Filter
550
Filtered Results: 550
Text search:
TB
comorbidities
Featured
Recommendations
73
New Publications
131
Language
Document type
No document type
305
Guidelines
105
Studies & Reports
84
Strategic & Response Plan
21
Manuals
16
Training Material
7
Fact sheets
5
Infographics
4
Situation Updates
2
Resource Platforms
1
Countries / Regions
India
23
South Africa
22
Kenya
21
Global
19
Western and Central Europe
17
Africa
14
Latin America and the Carribbean
13
Ethiopia
12
Namibia
11
Uganda
10
Ghana
9
Rwanda
9
Tanzania
9
Eastern Europe
8
Senegal
7
Congo, Democratic Republic of
7
Zambia
7
Nepal
6
Asia
6
South–East Asia Region
6
Bangladesh
6
Brazil
6
Ukraine
5
Nigeria
5
Sierra Leone
4
Malawi
4
Myanmar / Burma
4
Eswatini/ Swaziland
4
Lesotho
3
Burkina Faso
3
Zimbabwe
3
Cambodia
3
Russia
3
Georgia
3
Tajikistan
2
Colombia
2
Laos
2
Peru
2
Philippines
2
Germany
2
West and Central Africa
2
Western Pacific Region
2
East and Southern Africa
2
Argentina
2
Vietnam
2
Romania
2
Botswana
2
Liberia
2
North Macedonia
1
Timor Leste/ East Timor
1
Thailand
1
Chile
1
Cameroon
1
Syria
1
Estonia
1
Burundi
1
Guinea
1
Venezuela
1
Middle East and North Africa
1
Paraguay
1
Gabon
1
Côte d’Ivoire / Ivory Coast
1
Bolivia
1
Central African Republic
1
Mali
1
South Sudan
1
Somalia
1
Authors & Publishers
Publication Years
Category
Countries
209
Clinical Guidelines
80
Public Health
21
Capacity Building
3
Key Resources
3
Women & Child Health
2
Pharmacy & Technologies
1
Toolboxes
TB
164
HIV
106
COVID-19
45
Mental Health
14
NCDs
13
AMR
13
NTDs
9
Refugee
8
Ebola & Marburg
4
Pharmacy
4
Health Financing Toolbox
4
Conflict
4
Rapid Response
3
Caregiver
3
Polio
3
Disability
2
Cholera
1
Malaria
1
In case of resistance to rifampicin, fluoroquinolones become the preferred category of second-line drugs. Unfortunately, quinolone-resistant strains of Mycobacterium leprae have also been reported in several countries, probably due to the extensive use of quinolones for treating several types of inf...
Technical Update
HIV Treatment
July 2017
The European Journal of Public Health, Vol. 28, No. 1, 145–149
The Author 2017. Published by Oxford University Press on behalf of the European Public Health Association.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:...
This document outlines why and how nurses and midwives are important, not only for individual health optimization but also to achieve the thematic priorities of For the Future. More specifically, it provides case studies to showcase the amazing work that nurses and midwives across the Region are doi...
Guidelines
Key Populations
This report reviews the latest evidence on what works to reduce HIV-related stigma and discrimination through key programmes to reduce stigma and discrimination and increase access to justice in the six settings of focus for the Global Partnership. It includes guidance for national governments and k...
(Last Update: July 2022)
Putting Asia’s HIV response back on track
Countries reported disruptions in all health-care settings. In more than half of countries surveyed, many people are still unable to access care at the primary care and community care levels. Significant disruptions have also been reported in emergency care, particularly concerning given the impact...
Q&A on COVID-19, HIV and antiretrovirals - Hỏi Đáp về COVID-19, HIV và thuốc antiretrovirals (ARVs)
Arq Neuropsiquiatr 2011;69(2-B):342-348
It's time to deliver differently.
Accessed: 13.11.2019
The Lancet Infectious Disease Volume 25, Issue 2e77-e85February 2025
